Newron Pharmaceuticals SpA
SIX:NWRN

Watchlist Manager
Newron Pharmaceuticals SpA Logo
Newron Pharmaceuticals SpA
SIX:NWRN
Watchlist
Price: 6.9 CHF -2.95% Market Closed
Market Cap: 137.7m CHF

Relative Value

The Relative Value of one NWRN stock under the Base Case scenario is 10.43 CHF. Compared to the current market price of 6.9 CHF, Newron Pharmaceuticals SpA is Undervalued by 34%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

NWRN Relative Value
Base Case
10.43 CHF
Undervaluation 34%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
96
vs Industry
7
Median 3Y
10.5
Median 5Y
6.5
Industry
2.5
Forward
12.2
vs History
9
vs Industry
Median 3Y
-5.6
Median 5Y
-1.9
Industry
21.8
Forward
-4.4
vs History
vs Industry
Median 3Y
-9
Median 5Y
-3.1
Industry
16.6
vs History
vs Industry
Median 3Y
-8.1
Median 5Y
-5.4
Industry
24
vs History
9
vs Industry
Median 3Y
-4.8
Median 5Y
0.9
Industry
2.1
vs History
85
vs Industry
7
Median 3Y
12.9
Median 5Y
7.1
Industry
2.7
Forward
14.4
vs History
85
vs Industry
6
Median 3Y
13.9
Median 5Y
7.4
Industry
5.3
vs History
9
vs Industry
Median 3Y
-9.5
Median 5Y
-2.9
Industry
12.8
Forward
-6.2
vs History
9
vs Industry
Median 3Y
-9.3
Median 5Y
-2.9
Industry
16.2
Forward
-6.1
vs History
vs Industry
Median 3Y
-10.6
Median 5Y
-5.1
Industry
15.1
vs History
vs Industry
Median 3Y
-10.6
Median 5Y
-5.1
Industry
17.7
vs History
47
vs Industry
5
Median 3Y
8.5
Median 5Y
3.3
Industry
1.9

Multiples Across Competitors

NWRN Competitors Multiples
Newron Pharmaceuticals SpA Competitors

Market Cap P/S P/E EV/EBITDA EV/EBIT
IT
Newron Pharmaceuticals SpA
SIX:NWRN
137.7m CHF 2.9 9.3 6.6 6.7
US
Eli Lilly and Co
NYSE:LLY
743.9B USD 15.2 67.1 36 39.3
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
374.6B USD 4.2 17.2 12.6 16.5
DK
Novo Nordisk A/S
CSE:NOVO B
2T DKK 6.5 18.8 13 15
CH
Roche Holding AG
SIX:ROG
205.3B CHF 3.4 24.8 9.3 10.9
CH
Novartis AG
SIX:NOVN
191.2B CHF 4.5 18.7 11 14.7
UK
AstraZeneca PLC
LSE:AZN
160.1B GBP 4 28 130.7 197.1
US
Merck & Co Inc
NYSE:MRK
209B USD 3.3 12 8.9 10.8
IE
Endo International PLC
LSE:0Y5F
185.4B USD 79.9 -63.4 294.8 739.4
US
Pfizer Inc
NYSE:PFE
144.5B USD 2.3 18.4 7.8 11
P/E Multiple
Earnings Growth PEG
IT
Newron Pharmaceuticals SpA
SIX:NWRN
Average P/E: 23.8
9.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
67.1
49%
1.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
17.2
27%
0.6
DK
Novo Nordisk A/S
CSE:NOVO B
18.8
18%
1
CH
Roche Holding AG
SIX:ROG
24.8
32%
0.8
CH
Novartis AG
SIX:NOVN
18.7
17%
1.1
UK
AstraZeneca PLC
LSE:AZN
28
36%
0.8
US
Merck & Co Inc
NYSE:MRK
12
17%
0.7
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -63.4 N/A N/A
US
Pfizer Inc
NYSE:PFE
18.4
30%
0.6
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
IT
Newron Pharmaceuticals SpA
SIX:NWRN
Average EV/EBITDA: 397.9
6.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
36
30%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
12.6
7%
1.8
DK
Novo Nordisk A/S
CSE:NOVO B
13
13%
1
CH
Roche Holding AG
SIX:ROG
9.3
5%
1.9
CH
Novartis AG
SIX:NOVN
11
5%
2.2
UK
AstraZeneca PLC
LSE:AZN
130.7
10%
13.1
US
Merck & Co Inc
NYSE:MRK
8.9
8%
1.1
IE
E
Endo International PLC
LSE:0Y5F
294.8
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.8
2%
3.9
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
IT
Newron Pharmaceuticals SpA
SIX:NWRN
Average EV/EBIT: 1 705.8
6.7
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
39.3
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.5
13%
1.3
DK
Novo Nordisk A/S
CSE:NOVO B
15
14%
1.1
CH
Roche Holding AG
SIX:ROG
10.9
6%
1.8
CH
Novartis AG
SIX:NOVN
14.7
10%
1.5
UK
AstraZeneca PLC
LSE:AZN
197.1
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.8
11%
1
IE
E
Endo International PLC
LSE:0Y5F
739.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
11
10%
1.1